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Introduction 
This guideline is an update of the first G6PD guideline [The Assessment of Glucose-
6-Phosphate Dehydrogenase Deficiency; prepared by the General Haematology 
Task Force, 1991]. Data from recent External Quality Assessment (EQA) exercises 
show that there is continued variation in both the results obtained and laboratory 
practice and this may be sufficient to affect clinical outcome. The guideline is for use 
by staff working in diagnostic laboratories and is intended to promote the 
harmonisation of analytical methods through sharing best practice in the diagnosis of 
G6PD deficiency. 
Background 
Glucose-6-phosphate dehydrogenase (G6PD) is a housekeeping enzyme expressed 
in all tissue cells where it catalyses the first step in the pentose phosphate pathway. 
In the red blood cell, this is the sole pathway for the production of NADPH, which is 




impairs the ability of the red cell to deal with oxidative stress, which may lead to 
haemolytic episodes and anaemia that can be severe and in some cases fatal. 
G6PD deficiency shows marked genetic heterogeneity. Minucci and colleagues 
described some 186 mutations (Minucci et al. 2012) since when an additional 31 
mutations have been reported (Gomez-Manzo et al. 2016). However, of the 
estimated 400 million people worldwide that have G6PD deficiency, a few 
polymorphic mutations account for the vast majority (Vulliamy et al. 1988). The most 
common G6PD variants are found in people who originated from the Mediterranean 
countries (the Mediterranean type), parts of Africa (the African type; G6PD A-) and 
parts of India and South East Asia (Beutler 1971, Grimes 1980, Wintrobe 1981, 
Dacie 1985).  
DNA sequence analysis has shown that the vast majority of mutations arise from 
single amino acid substitutions, mostly leading to a decrease in enzyme stability or to 
reduced catalytic efficiency. The degrees of enzymatic dysfunction detected in 
variants have been found to be in accordance with the severity of the clinical 
manifestations (Vulliamy et al. 1998, Gómez-Manzo et al. 2017). A list of G6PD 
variants can be found at http://www.bioinf.org.uk/g6pd/db. 
The gene encoding G6PD is located near the telomeric region of the distal arm of the 
X chromosome (band Xq28) in a region that includes the genes for haemophilia A, 
dyskeratosis congenita and colour blindness. The G6PD gene consists of 13 exons 
and spans 18.5 Kb, with a GC-rich promoter region (Persico et al. 1986). Being X-
linked, males can be either hemizygous normal or hemizygous deficient, whereas 
females may be either homozygous normal, homozygous deficient or heterozygous. 




and cells expressing a deficient variant. The variable proportion of normal and 
deficient red cells, as a consequence of random X-chromosome inactivation 
(Lyonisation), renders diagnosis in some female heterozygotes difficult. A fraction of 
red cells in heterozygotes (on average, 50%) is as enzyme-deficient as in 
hemizygous males and therefore susceptible to haemolysis. Such individuals are 
usually less severely affected than homozygous females or hemizygous males. The 
severity of haemolysis and its potential clinical complications are roughly proportional 
to the fraction of deficient red cells. As a result of the random nature of X-
chromosome inactivation during embryogenesis, individual females can manifest 
skewing in favour of either the normal or deficient G6PD allele. The latter, if extreme, 
will result in most red cells being G6PD deficient and therefore susceptible to 
haemolysis.  
The great majority of G6PD-deficient individuals have no clinical manifestations in 
the steady state and the condition remains undetected until they are exposed to an 
exogenous haemolytic trigger such as bacterial or viral infections, ingestion of fava 
beans (favism) or drugs. However, some G6PD-deficient individuals suffer from a 
chronic non-spherocytic haemolytic anaemia (CNSHA), often requiring blood 
transfusion, in some cases on a long-term basis. These are due to the so-called 
Class 1 variants, in which G6PD activity is less than 10% of normal (Table 1; 
adapted from (Luzzatto et al. 2016). 







Class (% of normal)a Clinical Manifestations
Ib <10c CNSHAd (NNJ, acute exacerbations)
II <10c None in the steady state
III 10-60 None in the steady state
IV 100 None
V >100 None  
CNSHA, chronic non-spherocytic haemolytic anaemia 
NNJ, neonatal jaundice 
a Levels of residual G6PD activity in hemizygous males. 
b The definition of class I variants is not biochemical but clinical (i.e., class I variants cause CNSHA). 
C The range of G6PD activity is similar in class I and class II variants, which may seem strange 
because the clinical phenotype is significantly different. It must be considered, however, that (1) in 
CNSHA, there is always reticulocytosis, which increases G6PD levels, and (2) in some class I 
variants, the residual G6PD activity may be similar to a class II or even a class III variant, but the 
enzyme kinetics may be unfavourable. 
d When haemolysis is not compensated, chronic anaemia is present and blood transfusions may be 
necessary at times or even at regular intervals. 
 
G6PD deficiency is never complete, as this is not compatible with survival, but 
enzyme activity may be so low as to be undetectable in red blood cells by standard 
methods. As the red cells age in the circulation there is a gradual reduction in G6PD 
activity and the mean value in young red cells has been shown to exceed that of old 
red cells by a factor of 8.5 (Bonsignore et al. 1964).  
One of the most clinically significant complication of G6PD deficiency is neonatal 
jaundice (NNJ), which peaks 2 to 3 days after birth (Luzzatto 2010). Although highly 
variable in severity, without effective treatment it can lead to bilirubin encephalopathy 
(kernicterus) and permanent neurological damage or death. Haemolysis does not 
seem to contribute as much as impaired bilirubin conjugation and clearance by the 
liver (Kaplan et al. 1996). G6PD-deficient newborn babies who also inherit a 
mutation of the uridine-diphosphate-glucuronosyltransferase 1 (UGT1A1) gene 




jaundice (Kaplan et al. 1997). Neonatal screening for G6PD deficiency is routinely 
performed in many countries, mainly on dried blood spots, though not in the UK at 
the time of publication. 
Both favism and G6PD-related NNJ are often regarded as being primarily disorders 
of males: there are many more hemizygous deficient males than homozygous 
deficient females. However, both favism and NNJ are well documented in females, 
including heterozygotes (Meloni et al. 1983, Meloni et al. 1992, Luzzatto 1993). The 
offending chemicals present in fava beans (broad beans), particularly in the fresh 
green beans, are divicine and isouramil, powerful oxidising agents which result 
respectively from hydrolysis of the alkaloid glucosides vicine and convicine. While 
intrauterine haemolysis in G6PD-deficient fetuses exposed passively to fava beans 
appears rare, neonatal favism has been reported (Mentzer and Collier 1975, Corchia 
et al. 1995). Postnatal haemolysis through breast milk intake after maternal ingestion 
of fava beans is a recognised cause of NNJ (Yeruchimovich et al. 2002, Al-Azzam et 
al. 2009). Although placental transfer of the culpable agents in fava beans has not 
been demonstrated, other glucosides are known to be transferred.  
Accidental ingestion of mothballs containing naphthalene was one of the more 
frequent causes of acute haemolysis in G6PD deficiency in the UK (Santucci and 
Shah 2000), but is less common now as naphthalene-containing products have been 
banned in the EU since 2008. 
Bacterial and viral infections are known triggers of acute haemolytic anaemia in 
G6PD-deficient individuals although the mechanism of haemolysis is not well 
defined. Reactive oxygen species (ROS) have been implicated in the pathogenesis 




haemolysis has been attributed to hepatitis viruses A and B, cytomegalovirus, 
pneumonia and typhoid fever (Cappellini and Fiorelli 2008). After severe trauma, 
G6PD-deficient individuals may be at higher risk of sepsis and once infected may 
have a more severe clinical course (Spolarics et al. 2001). 
Some antimalarial drugs cause significant oxidative stress to the red cell and 
therefore it is important to test patients for G6PD deficiency before starting 
antimalarial therapy with these specific drugs. However, careful consideration for 
delaying treatment is required in what may be a life-threatening malaria. Although 
many drugs have been claimed to cause haemolysis in G6PD deficiency, in only a 
few of these is there a well-documented causal relationship (Table 2; from (Luzzatto 
and Seneca 2014) and the British National Formulary).  
Table 2. Drugs that can trigger haemolysis in G6PD-deficient subjects 
 
Category of drug  Predictable haemolysis Possible haemolysis 
 
Antimalarials   Dapsone   Chloroquine 




Analgesics/Antipyretic  Phenazopyridine  Aspirin (high doses)b 
Paracetamol (Acetaminophen) 
Antibacterials   Cotrimoxazole   Sulfasalazine 
    Sulfadiazine 
    Quinolonesc  
Nitrofurantoin 
Other    Rasburicase   Chloramphenicol 
    Toluidine blue   Isoniazid 




    Pegloticase   Glibenclamide 
        Vitamin K (Menadione) 
        Isosorbide 
        Dinitrate 
 
a not on UK market 
b acceptable up to a dose of at least 1 g daily in most G6PD-deficient individuals 
c including ciprofloxacin, moxifloxacin, nalidixic acid, norfloxacin and ofloxacin 
 
G6PD deficiency should also be considered in other clinical situations as described 
in Table 3. Although it has been claimed that haemolysis is usually not as severe 
with the African variant, drug-induced acute haemolytic anaemia in G6PD A- 
subjects can be life-threatening, therefore in clinical terms, the A- type of G6PD 
deficiency cannot be regarded as benign. 
The severity and course of a haemolytic episode depend both on the G6PD variant 
and the type and duration of oxidative stress. In addition, the age of the individual 
and any coexisting disease conditions are factors. Little is understood about how 
G6PD deficiency interacts with other genetic traits that affect red cell structure or 
function. In populations where G6PD deficiency is prevalent, haemoglobin S and 
thalassaemia coexist at a significant frequency. Some studies have suggested that 
co-inheritance of sickle cell anaemia and G6PD deficiency is associated with more 
severe anaemia and greater risk of cerebrovascular disease, although this has not 
been found consistently (Rees et al. 2009). G6PD testing in sickle cell disease and 
thalassaemic disorders is nevertheless recommended to avoid exposure of G6PD-
deficient individuals to oxidant drugs or other agents that may exacerbate anaemia in 
the context of chronic haemolysis. The impact of transfusing blood from G6PD-





Table 3. Indications for G6PD testing 
 
Prior to treatment with certain antimalarial or other 'oxidant' drugs (see Table 2) 
Haemolytic anaemia in the newborn (non-immune) 
Prolonged or severe neonatal jaundice 
Haemolysis associated with 'oxidant' drugs (see Table 2) or infection 
Favism 
Red cell morphology suggestive of oxidant damage or positive Heinz body stain 
Congenital non-spherocytic haemolytic anaemia in males or females 
Haemoglobinuria 
Sickle cell disease*  
Thalassaemic disorders 
Family history of G6PD deficiency or favism 
Patients likely to need rasburicase, such as those with leukaemia, lymphoma or other malignancies 
Acute haemolysis following haemopoietic stem cell transplantation if donor is G6PD deficient or status 
unknown
 
*Sickle cell anaemia and compound heterozygous states 
 
Specimen collection and storage 
For quantitative assays and for the fluorescence screening test, blood anticoagulated 
with ethylenediamine tetra-acetic acid (EDTA), heparin or acid-citrate-dextrose 
(ACD) solution can be stored for up to 3 weeks at 4°C or up to 5 days at room 
temperature with less than 10% loss of G6PD activity (Beutler 1984). Samples 
containing variants may be less stable than samples containing the normal enzyme. 
However a fresh sample (less than 24 hours old) is required for dye decolourisation 
tests and heparin should not be used as an anticoagulant as it may affect the 
decolourisation time. The cytochemical test must be carried out on the day of blood 
collection if anticoagulated with EDTA or heparin, or within 1 week if ACD is used. 
Since G6PD in haemolysates is unstable at room temperature, 4°C or - 20°C, 




Recommendations: sample collection and storage 
 Whole blood samples should not be stored for more than 5 days if 
anticoagulated with EDTA or not for more than 3 weeks if anticoagulated 
with ACD (one week for cytochemical test) (GRADE 1C). 
Principles of measurement of G6PD activity 
G6PD promotes the conversion of its specific substrate glucose-6-phosphate (G6P) 
to 6-phosphoglucono--lactone (6PGL) with a simultaneous reduction of the 
coenzyme NADP to NADPH. The 6PGL produced undergoes hydrolysis either 
spontaneously or via lactonase to 6-phosphogluconate (6PG), and is the substrate 
for the next enzyme in the metabolic pathway, 6-phosphogluconate dehydrogenase 
(6PGD), which is also present in the red cells, and which also reduces an additional 
amount of NADP to NADPH. Since NADPH is produced by both reactions, the only 
way to measure true G6PD activity is by carrying out assays with two different 
reaction mixtures: one containing an excess of both G6P and 6PG and the other 
containing only 6PG. The difference in activity between the first (G6PD + 6PGD) and 
the second (6PGD) assay gives the true G6PD activity (Glock and McLean 1953): 
Although this assay can be regarded as more accurate for certain research 
purposes, it is not necessary for diagnostic purposes. Indeed, for G6PD deficiency it 
tends to introduce an error greater than the one it is meant to correct for. The WHO 
(World Health Organization 1967) method which measures the overall reaction is 
satisfactory and is simpler to perform. Commercial kits simulate the Glock & McLean 
method by incorporating maleimide in their reagent to inhibit the 6PGD activity. All 
tests for measuring G6PD activity depend on detecting the rate of reduction of NADP 




1 Absorption of light at 340 nm.  
2 Fluorescence produced by long wavelength UV light (approximately 340 nm). 
3 Ability to decolourise or lead to the precipitation of certain dyes. 
In recent years, affordable, qualitative ‘point of care’ (POC) lateral flow tests have 
become available. These tests generally require capillary blood from finger-prick, 
and can be performed and interpreted by health workers at the bedside or in the field 
in <30 minutes. These cassette-based enzyme chromatographic devices are based 
on the reduction of colourless nitroblue tetrazolium dye to dark coloured formazan. 
However, to address the problem of misclassification of females with intermediate 
G6PD activities, more sophisticated quantitative POC devices have been developed 
that accurately measure G6PD activity normalised for haemoglobin concentration by 
reflectometry/spectrosocopy (Bancone et al. 2018, Pal et al. 2019). 
Cytochemical staining to demonstrate intracellular G6PD activity presents an 
alternative way to assess G6PD deficiency, and because it assays intact red blood 
cells, it can identify heterozygous females. Staining allows visualization (by 
microscopy) or enumeration (by flow cytometry) of the two distinct red cell 
populations resulting from the G6PD-normal and G6PD-deficient erythrocytes. 
Recommendation: principles of measurement of G6PD activity 
 Check the absorbance of the spectrophotometer for NADPH at the 
bandwidth (slot width) used and use the value obtained in your 
calculations.  The theoretical molar extinction (of 6.22) is only obtained 






If a male patient is suspected of having G6PD deficiency on clinical grounds, either 
the fluorescent spot or the dye decolourisation screening test are acceptable first-line 
tests. The complications of a raised WBC, raised retics, low Hb (and the inability to 
reliably identify female carriers) must be understood. If the screening test is 
abnormal or equivocal, the quantitative assay should be undertaken to confirm, or 
exclude, the diagnosis unless the patient is known to the laboratory. It is best to 
proceed directly to quantitative assay for female patients, who may be heterozygous 
and thereby possibly misclassified by any screening test. It is up to the individual 
laboratory to use either the one substrate (WHO) assay or the Glock and McLean 
(Glock and McLean 1953) technique. 
If a woman has an intermediate or equivocal result in the quantitative assay then the 
cytochemical test should be undertaken. If there is a clinical or genetic reason to 
suspect that a woman is heterozygous for G6PD deficiency then the cytochemical 
test should be undertaken even if the quantitative assay is normal because the 
cytochemical test may be the only way to detect a deficiency in some cases (other 
than by DNA analysis). After a haemolytic episode all tests may give normal or 
equivocal results in G6PD deficiency; therefore, it is recommended that a patient is 
retested following a haemolytic episode of unknown cause to ensure that G6PD 
deficiency is not missed. In this clinical scenario, the WHO quantitative technique is 
satisfactory but suffers the disadvantage that the activity of 6-phosphogluconate 
dehydrogenase is not measured and therefore this test cannot be used to assess the 
effect of young red cells and reticulocytes. After a haemolytic episode or if the 




informative with respect to interpretation. Alternatively, comparison with the activity 
of either PK or HK assayed in parallel often proves helpful. 
If G6PD deficiency is confirmed, the implications should be explained to the patient 
(or parent) who may also be given a 'card' or information leaflet containing the 
relevant information. A suggested format for such a card is given in the Appendices. 
A description of various laboratory tests which may be used for the diagnosis of 
G6PD deficiency together with useful practical points can be found in the 
Appendices. Laboratories undertaking these screening tests and assays should 
participate in External Quality Assessment Schemes. 
Reagent costs for these procedures are relatively inexpensive and readily obtainable 
from reliable biochemical supply manufacturers. However, the complexity of the tests 
requires experienced laboratory staff and some costly equipment (e.g. 
spectrophotometer). Commercially available kits for screening/assay are more 
straightforward to perform and generally provide a cost-neutral alternative to the 
procedures described below. 
Recommendations: Laboratory diagnosis 
 Do not rely on screening tests for female patients; measure G6PD 
activity by quantitative spectrophotometric assay directly (GRADE 1C). 
 The quantitative assay must be carried out if the screening test is 
abnormal or borderline (GRADE 1C). 
 Re-assay following a haemolytic episode of unknown cause to ensure 




Data from External Quality Assessment (EQA) G6PD surveys show that there is 
continued variation in both the results obtained and laboratory practice of 
participants. As this may be sufficient to affect clinical outcomes, several 
recommendations are given with particular reference to the quantitative assay. 
 Since the G6PD reaction is temperature dependent, an accurate cuvette 
temperature is very important (GRADE 1C): 
(a) Where possible, measure the temperature inside the reaction cuvette 
using a certificated thermometer/thermistor. Use a thermostatically 
controlled, recirculating water bath or a Peltier heating component 
attached to the spectrophotometer or use an automated analyser for the 
assay. 
(b) Run assays at either 30ºC or 37ºC. In laboratories without air-
conditioning, a temperature of 37ºC may be easier to control than 30ºC 
unless a cooling unit is available (and these are expensive). 
(c) Allow the assay mixture or reagents to equilibrate at the assay 
temperature before starting measurements. 
(d) Report results at the temperature assayed, rather than use a 
‘correction factor’ to adjust the numeric results to those that might have 
been achieved at a different temperature. 
 Run controls with every batch of samples: a normal and deficient 
sample obtained through a commercial company is preferable to an in 




 White cells contain a significant amount of G6PD, and ideally they 
should be removed prior to assay, and especially if the count is above 
the lab’s reference interval upper limit: Consider removal of white cells 
with a cellulose/‘real’ cotton wool column before assay (see Beutler, 
1984) (GRADE 1C). 
 Perform assays in duplicate if assays are undertaken only infrequently 
(GRADE 1C). On normal samples, the results of these duplicates should 
be within 0.5 iu/g of haemoglobin of each other (GRADE 1C). 
 Establish a laboratory reference range by in-house testing; referring to a 
kit manufacturer’s leaflet (if using a commercial kit) or literature search 
only as a guide (GRADE 1C). 
 Check that the assay absorbance increases in a linear fashion (it may 
take a minute or two for this to be achieved) and measure the 
absorbance over 10 minutes at 20 second intervals (for non-kit methods) 
(GRADE 1C). 
 Measuring the haemoglobin concentration of the haemolysate is just as 
important as measuring the enzyme activity, as both measurements will 
affect the final result to a similar extent. Similarly with well mixed whole 
blood where a kit indicates such use (GRADE 1C). 
Normal values 
The normal range for G6PD activity should be determined in each laboratory 
whether using an ”in-house” (ICSH) procedure or a commercial kit. It is not 




will provide a false-normal result on many heterozygotes. If the ICSH method is 
used, values should not differ widely from the published values. Results are 
expressed in international units (iu), which are the µmoles of substrate converted per 
minute. For adults, these values are 8.7 ± 1.7 iu/g haemoglobin at 30°C; 12.1 ± 2.09 
iu/g haemoglobin at 37°C (without correction for 6-PGD activity) and 8.34 ± 1.59 iu/g 
haemoglobin at 37°C (corrected for 6-PGD activity).  
Newborns and infants have enzyme activities that deviate appreciably from the adult 
value (Konrad et al. 1972). In one study, the newborn mean activity was about 150% 
of the adult mean (Oski 1969). G6PD activity has been found to be higher in 
premature infants born between 29 and 32 weeks gestation than in term neonates 
(Mesner et al. 2004). 
The Laboratory Report 
The report should conform to the requirements of the international standard 
(currently) “ISO 15189:2012 – Medical laboratories – Requirements for quality and 
competence”. Screening test results should be reported either as “normal”, 
“deficient” or “equivocal – please repeat”, and the results of quantitative assays 
should include the enzyme activity, the unit of measurement (iu/g haemoglobin or 
1012 rbc) or whether the result is expressed as a ratio. In addition, the assay 
temperature and the reference interval should be stated, together with the 
reticulocyte count. An interpretation of the result and recommendation(s) for action 
that reflect the clinical question being asked should be included. 
Factors affecting clinical interpretation 
With some G6PD variants, including the African type, young red cells and particularly 




tests carried out during, or soon after, a haemolytic episode may result in normal or 
even raised enzyme levels producing a false-normal result. In heterozygous females, 
the impact of selective haemolysis of G6PD-deficient red cells may compound the 
effect of reticulocytosis and the enzyme activity of residual non-deficient cells can 
mask the diagnosis of G6PD deficiency. Where G6PD deficiency is suspected on 
clinical grounds and no alternative explanation for haemolysis is forthcoming a G6PD 
assay should be repeated at least 2-3 months after resolution of the haemolytic 
episode. In this situation, examination of a blood film for typical features of oxidant 
damage is very important and is usually spectacular – almost diagnostic on its own – 
only if done very promptly, within 2 days from the onset of the haemolytic episode. If 
clinically indicated, to avoid delay it is possible to apply a 'correction' for the 
presence of young red cells and reticulocytes by measuring G6PD activity in the 
heaviest (oldest) red cells after microhaematocrit centrifugation (Herz et al. 1970). 
Alternatively, since the activity of several other red cell enzymes is similarly affected 
by the red cell age, comparison of their activity to that of G6PD can be undertaken. 
This approach also takes into account the effect of older cells lost by haemolysis. 
Hexokinase (HK), pyruvate kinase (PK) and 6-phosphogluconate dehydrogenase 
may be used for this purpose. 6PGD is the most convenient since it is assayed as 
part of the Glock and McLean procedure (see Appendix), which forms the basis of 
the International Council for Standardization in Haematology (ICSH) recommended 
method for G6PD assay (ICSH 1977). If HK, PK or 6PGD activity is raised in the 
presence of a G6PD level at the lower end of the ‘reference’ range it is likely G6PD 
activity would be subnormal in the absence of haemolysis and with a ‘normal’ age 
distribution of red cells. Improved identification of heterozygotes by utilizing the 




Samples with a very low MCH (<25 pg), as seen for example in thalassaemia, 
frequently give G6PD activity levels above the reference range, so values falling 
within range (especially at the lower end) should be viewed with caution and 
confirmatory molecular testing considered if clinically indicated. Sanna and 
colleagues (Sanna, et al. 1980) found this was a particular issue when G6PD levels 
are expressed as activity per g of haemoglobin and to lesser extent as activity per 
number of red cells x 109. 
Sex chromosome aneuploidy is a rare cause of uncertainty in the interpretation of 
G6PD activity. Male individuals with Klinefelter syndrome (XXY) may have 
intermediate levels similar to those of heterozygous females. Conversely in Turner 
syndrome (XO), G6PD activity may be as low as that seen in hemizygous deficient 
males or in women with extreme Lyonisation. 
All screening tests are useful to differentiate between normal and grossly deficient 
samples, but none of these techniques can reliably detect G6PD deficiency in 
heterozygous women. Equivocal results are difficult to interpret. It is advisable that 
the activity of these as well as of all deficient samples be confirmed by quantitative 
assay wherever possible. 
Anaemic samples and samples with a high leucocyte count can give misleading 
results in both screening tests. These problems can be avoided if the buffy coat is 
removed and packed red cells are used instead of whole blood. 
Recommendations: clinical interpretation 
 The final G6PD activity should be interpreted in light of the reticulocyte 




 The MCH (pg) of the test sample should be taken into account, as very 
low values (as seen in thalassaemia and iron deficiency) will 
overestimate the G6PD level where results are expressed in units per g 
haemoglobin (GRADE 1D). 
Point of Care Tests 
G6PD “point of care” (POC) is an area of rapid development with a number of 
different commercial products on the market and in development. Undoubtedly these 
will be invaluable both for mandated neonatal screening programs and in the use of 
8-aminoquinolines for the elimination of Plasmodium vivax malaria especially in 
“outreach” areas. However, they need not be limited to out of lab or field testing as 
they have potential to be used as a laboratory screening test, especially when a 
rapid result is required such as for anti-malarial treatment or Rasburicase 
administration. It is essential that any kit is evaluated for its fitness for purpose 
before use, especially with reference to storage temperatures, impact of 
environmental conditions and whether or not the kit incorporates a reference or 
control line where appropriate. 
Molecular diagnosis 
Molecular analysis should be considered in cases where a precise diagnosis is 
required for clinical reasons, e.g. to confirm the condition in a recently transfused 
patient, a heterozygous female or where a deficiency may be masked by a 
reticulocytosis. It should be remembered that molecular analysis may not detect all 
variants and that it does not reflect the functional activity of the enzyme in all 





The majority of G6PD mutations are point mutations and to date, 217 have been 
identified worldwide in both the coding DNA, introns and the 5’ and 3’ untranslated 
regions. There are common mutations in certain geographical areas such as the 
Mediterranean mutation and the G6PD A- in Africa and so one potential approach is 
to use a targeted direct mutation analysis method such as polymerase chain 
reaction-restriction fragment length polymorphism (PCR-RFLP) (Poggi et al. 1990) 
aimed at these particular mutations. If this method produces a negative result or if 
there are no clear common mutations or if geographical origin is unclear then direct 
Sanger sequencing (Sanger and Coulson 1975, Minucci et al. 2008) can be 
performed, which will also detect less common and novel mutations. Given the 
improvements in efficiency and cost of Sanger sequencing and the considerable 
heterogeneity of the mutations encountered in G6PD deficiency, proceeding directly 
to Sanger sequencing has become a more widely used approach. A positive result 
from this sequence analysis can be regarded as a stand-alone diagnostic result. 
However, if a mutation is not found, then only a quantitative assay can establish 
G6PD deficiency. The recent advances in next generation sequencing have also 
made it possible for many genes related to red cell disorders to be sequenced 
simultaneously. This means that in cases of unexplained haemolysis, all potential 
genes related to red cell enzyme deficiency can be looked at in a single molecular 
assay rather than several molecular and biochemical tests. 
It should be noted that in heterozygous females, molecular analysis is likely to be the 
only method of definitive identification of carrier status. 




 Molecular analysis can be undertaken if results of initial diagnostic 
procedures are equivocal or borderline, especially in (heterozygous) 
woman and male individuals with Klinefelter syndrome (XXY) who may 
have intermediate levels similar to those of heterozygous females 
(GRADE 1D). 
Quality assurance 
Quality assurance is the process by which the laboratory demonstrates that the 
diagnostic results it produces are reliable in terms of accuracy and precision. In 
addition to the inclusion of internal quality control materials with each batch, a key 
element in quality assurance is participation in an accredited external quality 
assessment (EQA) programme, where available. EQA for G6PD qualitative and 
quantitative tests is offered by the major national and international EQA 
organisations and the laboratory should understand the type of programme provided 
and how it should be used in the laboratory to gain maximum benefit from 
participation (James et al. 2014). EQA is not available for the cytochemical assay 
and a laboratory undertaking this test should consider some other means of 
interlaboratory comparison, e.g. sample exchange. The frequency of EQA 
distributions, the inclusion of specimens that test the laboratory at clinical decision-
making activities and the regular review of EQA results are particularly important. 
Any out-of-consensus EQA result should be fully investigated. 
Recommendations: Quality assurance 
 Laboratories undertaking these screening tests and assays should 
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Fig. 1. Example of card template to be carried by a patient with G6PD deficiency 
 
Appendix 2 
Fluorescent Spot Test 
Reagent kits for both the fluorescent spot test (e.g. Trinity Biotech Qualitative G6PD 
FST Kit; catalogue number 203-A) and the dye decolourisation test (Trinity Biotech 
G-6-PDH Deficiency Screen Kit; catalogue number 400k) can be obtained 
commercially.* Such kits have the advantage of being “CE” ("Conformité 
Européene") marked and meet the requirements of the IVD (In Vitro Diagnostic 
                                            




Device) directive (98/79/EC), ensuring they are “fit for purpose”. The new In Vitro 
Diagnostic Device Regulation (EU) 2017/746, published in the Official Journal of the 
European Union on 5 May 2017, strengthens the approval system for in vitro 
diagnostics. 
A procedure based on the recommended method (ICSH 1979) is given below. Blood 
is mixed with an appropriate reaction mixture containing a detergent-like compound 
to lyse the red cells. After a standard time the mixture is 'spotted' onto filter paper, 
dried and inspected under long wavelength UV light. The appearance and brightness 
of the fluorescence due to NADPH gives a measure of the activity of G6PD. 
 
REAGENTS 
-NADP    7.5 mmol/l  2 ml 
Glucose-6-phosphate   l0 mmol/l  4ml 
Saponin    10 g/l   4ml 
Tris-HCI buffer†   0.75 mol/l, pH 7.8 6 ml 
Oxidized glutathione (GSSG) 8 mmol/l  2 ml 
Distilled water      2 ml 
TOTAL       20ml 
†It is essential to use a pH electrode which is suitable for Tris buffer. 
 
Mix the reagents in the volumes stated to make a total volume of 20 ml and then 
dispense this reaction mixture in 0.2 ml aliquots (e.g. in microfuge tubes) and store 
frozen at - 20°C. This mixture is stable for up to I year at this temperature. 
BLOOD SAMPLES 
Blood may be anticoagulated with EDTA (any sodium or potassium salt), heparin or 




give reliable results even after storage for up to 5 days at 25°C or for up to 21 days 
at 4°C. 
Method 
Thaw an aliquot of the reaction mixture and allow it to come to room temperature. 
Mix 20 μl of whole anticoagulated blood with 0.2 ml of reaction mixture. Spot one 
drop (20 μl) of this mixture onto non-fluorescent filter paper such as Whatman No. 1, 
as soon as it has been mixed, and again at intervals of 5 and I0 minutes from the 
mixing time. Examine the spots under long wavelength UV light as soon as they 
have thoroughly dried. Samples with a very high haemoglobin concentration (Hb) 
(e.g. cord bloods) should be diluted to match the Hb of the normal control (using 
plasma from the test sample), because “quenching” of the fluorescence has been 
noted with such samples. 
Note. The presence of GSSG in the reaction mixture increases the sensitivity of the 
method. This is because the GSSG allows the small amounts of NADPH which may 
be formed by residual G6PD in mildly deficient samples to be reoxidised by 
glutathione reductase, another enzyme present in the red cell haemolysate. 
Interpretation 
At the beginning of the incubation no fluorescence should be visible and the samples 
from people with normal G6PD activity will fluoresce after 10 minutes incubation. 
G6PD deficiency is indicated by delayed or absent fluorescence. 
Dye decolourisation screening test 
A freshly prepared haemolysate is added to the reaction mixture containing a 




by the NADPH produced gives a measure of the activity of G6PD. In the Motulsky 
Test (Motulsky 1959) the dye is brilliant cresyl blue, while in the Trinity colorimetric 
test (Procedure No. 400k), 2, 6-dichlorophenol indophenol is used. Unfortunately 
only certain batches of brilliant cresyl blue are suitable for the dye decolourisation 
test and so it is important that all new batches are tested for suitability. 
Motulsky et al. (1959) 
REAGENTS 
Stored reagents are stable for up to one year at the temperatures given. 
 -NADP   0.7 mmol/l. Freeze 1 ml aliquots at - 20°C 
Glucose-6-phosphate 30 mmol/l. Freeze 1 ml aliquots at - 20°C 
Liquid paraffin   Store at room temperature 
Buffer-dye mixture 0.7 mol/l Tris-HCl, pH 8.5, containing 320 mg/I brilliant 
cresyl blue. Freeze 4.5 ml aliquots at - 20°C. It is 
essential to use a pH electrode that is suitable for Tris. 
Working mixture  Thaw one aliquot of NADP, G6P and the buffer-dye 
mixture and mix together. 
 
BLOOD SAMPLE 
Blood should be anticoagulated with EDT A and used within 24 hours of collection. 
Make a haemolysate by adding 20 l of whole blood to 1 ml of water, mix well and 
use within 6 hours. Always include a control sample with normal G6PD activity and if 
possible a control sample with reduced G6PD activity. 
Method 
Add 0.65 ml of the working mixture to the haemolysate, mix and cover with a layer of 






Normal range 35-60 minutes 
G6PD deficiency 1.5-24 hours 
Note. In very anaemic subjects (Hct less than 0. 25) adjust the Hct to 0.4-0.5 before 
making the haemolysate. 
Cytochemical assay 
The technique described by Fairbanks and Lampe (Fairbanks and Lampe 1968) is 
satisfactory and is summarised below, although various attempts have since been 
made to improve the reliability of this procedure for detecting heterozygotes, such as 
“mild” fixation of the red cells and accelerating the reaction with an exogenous 
electron carrier, 1-methoxyphenazine methosulphate (Van Noorden and Vogels, 
1985; Gurbuz et al. 2005). The procedure is based on the fact that haemoglobin can 
reduce certain dyes to form a granular precipitate while methaemoglobin (MetHb) 
cannot do this. The test involves a preliminary incubation of red cells with nitrite to 
change all the haemoglobin to methaemoglobin. This is followed by a second 
incubation with a reaction mixture containing the dye. The presence of G6PD in the 
red cells leads to the formation of NADPH which reduces methaemoglobin to 
haemoglobin and hence precipitation of the dye to form granules. The presence of 
these granules in the red cells therefore indicates G6PD activity. Counting the 
granules in the red cells can give a semi-quantitative assessment of G6PD. This 
method may sometimes be the only way to identify G6PD deficiency in some 
heterozygous females. However in some women the effects of Lyonisation of the X-
chromosome are such that even this test may fail to detect the heterozygous state 





Fairbanks and Lampe (1968) 
REAGENTS: 
Sodium chloride 0.15 mol/l 
Sodium chloride 0.1 mol/l 
Sodium nitrite 0.18 mol/l 
MTT*   5 mg/ml  
Incubation mixture: Mix the following reagents so that the mixture will have the final 
concentration stated and divide into 1 ml aliquots which are 
stable for 3 weeks at 4°C or for at least I year at - 20°C 
Glucose (28 mmol/l), Phosphate buffer (50 mmol/ l, pH 7.0) 
Sodium chloride (58 mmol/l), and Nile blue sulphate (11 mg/I) 
*MTT = 3-(4,5-dimethylthiazolyl-2)-2, 5 diphenyltetrazolium bromide. 
 
BLOOD SAMPLES 
It is best to use blood anticoagulated in ACD (4 ml of blood in 1 ml of ACD) which 
can be used for up to 1 week after collection. Heparinized and EDTA blood samples 
can also be used, but must be used on the day of venesection to avoid excessive 
red cell crenation (affecting membrane permeability), or alternatively, transferred into 
ACD on the day of collection. 
Procedure 
1 Centrifuge sample, remove the supernatant plasma and add 0.5 ml of packed red 
cells to a centrifuge tube containing 9 ml 0.15 mol/l sodium chloride and 0.5 ml of 
0.18 mol/l sodium nitrite. Incubate undisturbed at 37°C for 20 minutes. 
2 Centrifuge at 4°C for 15 minutes at 550 g. Remove and discard the supernatant 




3 Wash the red cells three times with 9 ml of cold 0.15 mol/l sodium chloride at 4°C 
as in step 2 above. After each wash remove the buffy coat taking care to remove as 
few red cells as possible. 
4 Mix the packed red cells and transfer 50 l to a tube containing l.0 ml of the 
incubation mixture. Incubate undisturbed at 37°C for 30 minutes. 
5 Add 0.2 ml of MTT and resuspend the red cells by gentle agitation. Continue the 
incubation at 37°C for a further 60 minutes. 
6 Resuspend the red cells thoroughly and mix one drop of this suspension with one 
drop of 0.1 mol/l sodium chloride on a microscope slide and cover with a coverslip. 
7 Within 30 minutes of making the preparation examine 500 red cells with a x 100 oil 
immersion objective and score their granularity as follows: 
No granules    0 
1-3 granules    I + 
4-6 granules    2 + 
More than 7 granules 3 + 
Interpretation 
In subjects with normal G6PD activity most of the red cells will contain some 
granules and more than 30% will score 3 +. In deficient hemizygous males less than 
20% of the red cells will contain any granules and often only the youngest red cells 
(reticulocytes) will contain any granules. Mosaicism in heterozygous females should 
be easy to recognize since one population will have normal granules and the other 
population will have few or no granules. The results are often easier to interpret if 




More recently, a cytofluorometric method has been developed (Shah et al. 2012) 
which utilises flow cytometry to analyse the G6PD activity in individual red cells, and 
a new software tool (Kalnoky et al. 2014) has been designed to improve precision in 
measurements generated by different flow cytometers and to give better quantitative 
interpretation of cytochemical staining results. 
Quantitative assay 
The introductory chapters of Beutler's practical manual (Beutler 1984) contain very 
useful details concerning the preparation, stability and storage of reagents and 
calibration of spectrophotometers as well as details of the assay technique 
(unfortunately no longer in print). 
In the quantitative method, a recording spectrophotometer is helpful but the assay 
can be undertaken with any spectrophotometer which can measure absorbance at 
340 nm and in which the temperature of the cuvette can be maintained within 1-2°C 
at 30°C or 37°C. Since the activity of G6PD is calculated from the change in 
absorption at 340 nm due to the reduction of NADP to NADPH, it is important to 
know the millimolar extinction coefficient of NADPH in the spectrophotometer being 
used for the assay. In practice the millimolar extinction coefficient of 6.22 can be 
used (the absorption of a millimolar solution in a 1 cm cuvette at 340 nm) if the 
bandwidth of the spectrophotometer is 4 nm or less. If the bandwidth is broader than 
this it may be necessary to calibrate the spectrophotometer using an accurately 
prepared solution of NADPH since the extinction coefficient will fall as the bandwidth 
gets broader. In any case a normal range for a given laboratory (and 




Like all enzyme reactions, the chemical reactions associated with G6PD are affected 
by temperature: a higher temperature will lead to an increase in the reaction rate and 
will therefore appear to give both an increase in activity and an apparent loss of 
precision if assessed by the standard deviation, but no change in precision if 
assessed by the coefficient of variation. For the same reason the apparent sensitivity 
of the tests will increase with temperature. Since the effect of temperature can be 
significant, it is essential that the reaction is undertaken at a known constant 
temperature and that a 'normal range' is used which has been established at that 
temperature. Formulae have been drawn up to indicate the effect of temperature on 
reaction rate (Beutler, 1984) but these should not be relied on in a clinical situation. 
In practice it is much easier to control the temperature of the cuvette if the 
temperature chosen is significantly above ambient temperature, because most 
temperature controllers only have heaters and rely on the ambient temperature for 
cooling. 
It is important to remember that the normal range for G6PD activity by the WHO 
“one-substrate” (“one-stage”) method is different from (and higher than) that obtained 
using the Glock and McLean method (see Appendix). 
G6PD quantitative “one-substrate” assay 
BLOOD SAMPLES 
Blood samples may be anticoagulated with EDTA, heparin or ACD and give reliable 





Filtration of whole, anticoagulated blood through a mixed cellulose column to remove 
white cells and platelets is preferable but if this is not practical, centrifugation of the 
blood and removal of the plasma and buffy coat is satisfactory.  
Wash the red cells twice in cold 0.15 mol/l sodium chloride and then resuspend the 
red cells in an equal volume of cold 0.15 mol/l sodium chloride. Add 0.2 ml of the cell 
suspension to 1.8 ml of the haemolysing reagent consisting of 2.7 mmol/l EDTA, pH 
7.0, and 0.7 mmol/l 2-mercaptoethanol (100 mg of EDTA disodium salt and 5 µl of 2-
mercaptoethanol in 100 ml of water; adjust the pH to 7.0 with HCl or NaOH). 
Place the suspension on ice for 10 minutes to ensure haemolysis and mix before 
use. If lysis appears incomplete, freeze and thaw by placing the tube containing the 
haemolysate in an ice-alcohol mixture until it is frozen and then thaw by placing the 
tube in a beaker of water at room temperature. Next measure the haemoglobin 
concentration. This haemolysate should be kept cold (preferably in ice) and should 
be used within 2 hours. Removal of the stroma is not necessary. 
The haemolysate should be prepared freshly for each batch of enzyme assays. Most 
enzymes in haemolysates are stable for 8 hours at 0°C, but it is best to carry out 
assays immediately. G6PD is one of the least stable enzymes in this haemolysate, 
and its assay should be conducted within 1 or 2 hours of the lysate being prepared. 
The storing of frozen cells or haemolysates is not recommended; it is preferable to 
store whole blood in ACD. 
Procedure 
The assay is carried out at constant temperature (37°C or 30°C), the cuvettes 
containing the first three reagents and water plus haemolysate being incubated for 




change in absorbance following the addition of the substrate is measured over the 
first 10 to 15 minutes of the reaction. The value of the blank is subtracted from the 
test reaction, either automatically or by calculation. Commercial assay kits are also 
available.* 
The reaction involving G6PD can be written as follows: 
Glucose-6-P  +  NADP+    G-6-PD      6-PGA  +  NADPH  + H+ 
 
Table 3 Glucose-6-phosphate dehydrogenase assay 
Reagents Assay (µl) Blank (µl) 
0.1M Tris-HCl/0.5mMEDTA buffer, pH8.0 100 100 
MgCl2, 100 mmol/l 100 100 
NADP, 2 mmol/l 100 100 
1:20 Haemolysate   20   20 
Water 580 680 
Start reaction by adding: G6P, 6 mmol/l 100   – 
EDTA, ethylenediaminetetra-acetic acid; NADP, Nicotinamide adenine dinucleotide phosphate;   
G6P, glucose-6-phosphate. 
 
Calculation of enzyme activity 
The reaction rate, and therefore the rate of increase in absorbance at 340 nm, 
usually increases for the first few minutes, then becomes linear and finally slows 
down as the substrate is used up. 
The linear part of the curve over a 10 minute period is used for the calculation. Draw 
a straight line through the recorded points then read off the increase in absorbance 
and divide by 10 to obtain the increase in one minute (∆A). 
The activity of the enzyme in the haemolysate is calculated from the initial rate of 
change of NADPH accumulation: 
                                            
* Trinity Biotech, (Trinity Biotech, Bray, Co Wicklow, Ireland); Pointe Scientific (Pointe Scientific, Inc. 5449 




Enzyme activity in iu/g haemoglobin 
= 
change in absorbance at 340 nm/minute x dilution factor x 100
6.22 Hb  
 
where 6.22 is the mmol extinction coefficient of NADPH at 340 nm. Results are 
expressed per 1012 red cells, per ml red cells, or per g haemoglobin by reference to 
the respective values obtained with the washed red cell suspension. However, the 
ICSH recommendation is to express values per g haemoglobin, so the haemoglobin 
concentration must be measured on the haemolysate directly. 
Normal G6PD is very stable and with most variants venous blood may be stored in 
ACD for up to 3 weeks at 4°C without loss of activity. 
Some enzyme-deficient variants lose activity more rapidly, and this will cause 
deficiency to appear more severe than it is. Therefore, for diagnostic purposes, a 
delay in assaying well-conserved samples should not be a deterrent. 
 
G6PD quantitative assay incorporating Glock and McLean procedure 
See Beutler (1984) 
REAGENTS 
These may be stored at the temperatures given for up to l year. 
 
-NADP     2 mmol/l. Freeze 2 ml aliquots at - 20°C 
Glucose-6-phosphate   6 mmol/l. Freeze I ml aliquots at - 20°C 
6-phosphogluconate   6 mmol/l. Freeze I ml aliquots at - 20°C 
Magnesium chloride             0.1 mol/l Store at 4°C 
Sodium chloride    0.15 mol/l Store at 4°C 
Tris-HCI, I mol/l, EDTA 5 mmol/l,   Store at 4 °C 
pH 8.0  It is essential to use a pH electrode which is 




Haemolysing reagent Mix 0.05 ml of 2-mercaptoethanol and 10 ml 
of neutralised 10% (0.27 mol/l) EDTA and 
make up to I litre with water 
 
BLOOD SAMPLES 
Blood samples may be anticoagulated with EDTA, heparin or ACD and give reliable 
results after storage at 5 days at 25°C or 21 days at 4°C. 
Haemolysate 
Filtration of whole, anticoagulated blood through a mixed cellulose column to remove 
white cells and platelets is preferable (Beutler 1984), but if this is not practical 
centrifugation of the blood and removal of the plasma and buffy coat is satisfactory. 
Wash the red cells twice in cold 0.15 mol/l sodium chloride and then resuspend the 
red cells in an equal volume of cold 0.15 mol/l sodium chloride. Add 0.2 ml of the cell 
suspension to 1.8 ml of the haemolysing reagent. Freeze and thaw the haemolysate 
by placing the tube containing the haemolysate in an ice-alcohol mixture until it is 
frozen and then thaw by placing the tube in a beaker of water at room temperature. 
Next measure the haemoglobin concentration. This haemolysate should be kept cold 
(preferably in ice) and should be used within 2 hours. Removal of the stroma is not 
necessary. 
Procedure 
The reagents shown in Table 4 are added to cuvettes with a critical volume of less 
than l.0 ml. If cuvettes with a critical volume of less than 3 ml are used the volumes 
of all the reagents must be multiplied by three. 
Mix, incubate at constant temperature (37° or 30°C) and record the absorbance at 






    Cuvette 
1  2  3  4  
Tris-HCl, EDTA buffer  100*   100   100  100 
MgCl2    100   100   100  100 
NADP    100   100   100  100 
Water    680   580   580  480 
Haemolysate     20     20     20    20 
Mix and incubate at constant temperature for 10 minutes 
G-6-P      −  100    −  100 




The reaction rate, and therefore the rate of increase in absorbance at 340 nm usually 
increases for the first few minutes, then becomes linear and finally slows down as 
the substrates are used up. 
Use the linear part of the curve for the calculation. Draw a straight line through the 
recorded points then read off the increase in absorbance over a 10 minute period 
and divide by 10 to obtain the increase in one minute (∆A). 
Calculation 
Enzyme activity in iu/g haemoglobin 
=  
change in absorbance at 340 nm/minute x dilution factor x 100
6.22 Hb  
 
Where 'Hb' = Hb concentration of the haemolysate in g/dl. In the method given above 
this can be simplified to: 
G6PD (WHO method) 
=  iu/g haemoglobin ∆A (cuvette 2-cuvette 1)  x  804






G6PD (Glock & McLean method) 
= 
∆A (cuvette 4-cuvette 3)  x  804
Hb concentration of haemolysate (g/dl)   iu/g haemoglobin 
 
6PGD =
∆A (cuvette 3-cuvette 1)  x  804
Hb concentration of haemolysate (g/dl)   iu/g haemoglobin 
 
Where ∆A = change in absorbance in 1 minute. 
 
Normal values (mean ± 2SD at 37°C) 
G6PD (WHO method)   12.1 ± 4.2 iu/g haemoglobin 
G6PD (Glock & McLean method)  8.3 ± 3.2 
6PGD       8.8 ± 1.7 
It is important for each laboratory to establish its own normal range and to include a 
normal control sample with each assay. 
Interpretation 
The Glock and McLean method (cuvettes 4-3) is usually a more accurate expression 
of the true G6PD activity than the WHO method (cuvette 2-1). However, at very low 
enzyme activities this involves subtracting a large, experimentally determined value 
(6PGD, cuvette 3), from a slightly larger one (G6PD + 6PGD, cuvette 4). In this 
situation the WHO method (cuvette 2-1) is preferred. 
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